A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas

• DOI: 10.1016/j.ejso.2025.109721
• Publication Date: 2025-04-11T19:19:48Z
• Authors: Faye Lewis; Mark P. Ward; Feras Abu Saadeh; Catherine O'Gorman; Patrick J. Maguire; James P. Beirne; Waseem Kamran; Elzahra Ibrahim; Lucy Norris; Tanya Kelly; Sinéad Hurley; Brian Henderson; Marika Kanjuga; Lorraine O'Driscoll; Kathy Gately; Ezgi Oner; Volga M. Saini; Karen Cadoo; Cara Martin; John J. O'Leary; Sharon A. O'Toole
• Keywords: Ovarian carcinomas

Studies on circulating tumour cells (CTCs) in rare epithelial ovarian carcinomas (EOC) are limited, despite their potential as a minimally invasive biomarker for monitoring cancer progression and predicting outcomes. This pilot study aimed to assess the feasibility of enriching detecting CTCs from both peripheral vein blood samples EOC subtypes. Blood were collected veins 20 patients with EOC. Among patients, 12 had early-stage disease (I-II), while 8 advanced (III-IV). enriched using Parsortix® system immunophenotyped via immunofluorescence targeting markers (EpCAM/pan-cytokeratin) Hoechst positive selection, CD45 negative selection. CTC status (positive versus negative) was correlated clinicopathological data. successfully detected 45 % (1-19 CTCs) baseline 55 (1-4776 samples. doublets clusters (3/11), but not (0/20). A higher proportion deaths observed CTC+ compared CTC- (p = 0.0088). Here we demonstrate The yield suggests that tumour-draining may play role improving detection. paves way larger studies investigate prognostic utility refine clinical value these understudied